Can I Take NAC (N-Acetylcysteine) with Jardiance (Empagliflozin)?

What Is Empagliflozin and How Does It Work?

Empagliflozin (Jardiance) is a sodium-glucose cotransporter-2 (SGLT2) inhibitor approved by the FDA for type 2 diabetes mellitus, heart failure with reduced or preserved ejection fraction, and chronic kidney disease (CKD) [1]. It blocks glucose reabsorption in the proximal tubule of the kidney, producing around 70 g of urinary glucose excretion per day and a modest osmotic diuresis [2].

FDA-Approved Indications and Doses

The FDA label specifies 10 mg or 25 mg once daily for type 2 diabetes and 10 mg once daily for heart failure and CKD [1]. The EMPA-REG OUTCOME trial (N=7,020) demonstrated a 38% relative risk reduction in cardiovascular death with empagliflozin 10 or 25 mg vs. Placebo in adults with type 2 diabetes and established cardiovascular disease [3]. The EMPEROR-Reduced trial (N=3,730) showed a 25% reduction in the composite of cardiovascular death or heart failure hospitalization with empagliflozin 10 mg [4].

Metabolic Pathway

Empagliflozin is metabolized primarily through glucuronidation by UDP-glucuronosyltransferase (UGT) isoforms UGT1A3, UGT1A8, and UGT1A9, not through cytochrome P450 enzymes [1]. This matters for interaction prediction: most supplement-drug interactions involve CYP3A4 or CYP2D6. Because empagliflozin bypasses those pathways, the interaction risk profile with NAC differs substantially from drugs like warfarin or statins.

What Is NAC and Why Do People Take It?

N-acetylcysteine is a thiol-containing compound that serves as a direct precursor to glutathione, the body's primary intracellular antioxidant [5]. Clinically, intravenous NAC is the standard treatment for acetaminophen overdose. Oral NAC is used off-label for PCOS, liver support, mucolytic therapy in COPD, and antioxidant supplementation [6].

Common Doses in Clinical Trials

Most published trials use 600 mg once or twice daily for antioxidant indications. A randomized trial of NAC in PCOS (N=100) used 1,200 mg/day for 24 weeks and observed modest improvements in insulin sensitivity compared with metformin [7]. A Cochrane review of NAC in chronic obstructive pulmonary disease identified 600 to 1,200 mg/day as the standard dose range across included studies [8].

Pharmacokinetic Profile

Oral NAC has low bioavailability (approximately 4 to 10%) due to extensive first-pass metabolism [5]. It is hydrolyzed to cysteine in the liver, and neither NAC nor cysteine is a meaningful inhibitor or inducer of CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at clinical doses [5]. It does not bind to P-glycoprotein transporters in ways that would affect empagliflozin's absorption or clearance.

Is There a Known Drug Interaction Between NAC and Empagliflozin?

No interaction is listed in the FDA prescribing information for empagliflozin [1], and no pharmacokinetic interaction trial between NAC and empagliflozin has been published as of early 2025. The interaction databases that clinicians rely on most, including the FDA's drug interaction guidance framework, classify the combination as having no established interaction based on mechanism [1][5].

Why Pharmacokinetic Conflict Is Unlikely

The reasoning is straightforward. Empagliflozin depends on UGT glucuronidation [1]. NAC depends on hepatic thiol hydrolysis [5]. Neither compound inhibits the other's primary metabolic enzyme, transporter, or renal clearance mechanism. Protein binding for empagliflozin is approximately 86%, and NAC does not significantly displace highly protein-bound drugs at standard doses.

Where Caution Is Still Warranted

The absence of a direct pharmacokinetic clash does not mean the combination is entirely without consideration. Both agents can affect kidney tubular physiology and fluid balance in overlapping ways. Empagliflozin's osmotic diuresis reduces plasma volume by roughly 2 to 3% in the first weeks of therapy [2]. NAC at high doses (above 1,800 mg/day) has shown mild diuretic-like effects in animal models, though this has not been replicated at standard human doses [6]. Patients who are volume-depleted or who have CKD stage 3b or worse need closer monitoring when starting or continuing either agent.

Shared Renal Considerations

Empagliflozin and eGFR Dynamics

Empagliflozin causes an acute, hemodynamically mediated dip in eGFR of approximately 3 to 5 mL/min/1.73 m² in the first 2 to 4 weeks due to reduced intraglomerular pressure [9]. This is expected and does not represent true nephrotoxicity. In the EMPA-KIDNEY trial (N=6,609), empagliflozin 10 mg significantly slowed long-term eGFR decline compared with placebo (P<0.001) in patients with CKD, despite this initial dip [9].

NAC and Renal Tubular Antioxidant Effects

NAC has shown nephroprotective properties in contrast-induced nephropathy prevention studies [10]. A meta-analysis of 41 trials (N=4,416) found that prophylactic NAC reduced the incidence of contrast nephropathy by approximately 30% compared with hydration alone [10]. The proposed mechanism involves glutathione-mediated scavenging of reactive oxygen species in proximal tubular cells, the same cells where SGLT2 is expressed and where empagliflozin acts [5][10].

This means the two agents may theoretically complement each other in terms of tubular oxidative stress, though no clinical trial has directly tested that combination.

NAC, PCOS, and Empagliflozin Co-Use

Some patients with PCOS use NAC for insulin sensitization and may also be prescribed empagliflozin off-label for metabolic management. The previously cited PCOS trial using 1,200 mg NAC/day showed a statistically significant reduction in fasting insulin (P<0.05) after 24 weeks [7]. Empagliflozin, while not FDA-approved for PCOS, has been studied in small cohorts showing improvements in androgen levels and BMI [11].

Hypoglycemia Risk in This Population

Neither NAC nor empagliflozin (as monotherapy) causes clinically significant hypoglycemia. The EMPA-REG OUTCOME trial reported hypoglycemia rates of 5.1% with empagliflozin vs. 4.8% with placebo in participants not using insulin [3]. Adding NAC to empagliflozin does not add a hypoglycemic mechanism. The risk increases meaningfully only when empagliflozin is combined with sulfonylureas or insulin.

Monitoring Parameters When Taking Both

Baseline Tests Before Starting the Combination

Clinicians at HealthRX recommend the following before combining NAC with empagliflozin:

• Serum creatinine and calculated eGFR
• Urine albumin-to-creatinine ratio (UACR)
• Basic metabolic panel (sodium, potassium, bicarbonate)
• Blood pressure and volume status assessment

Follow-Up Monitoring Schedule

Repeat eGFR and creatinine at 4 weeks after initiating empagliflozin, then every 3 to 6 months. The FDA label for empagliflozin states: "Assess renal function prior to initiating JARDIANCE and periodically thereafter" [1]. Patients with eGFR <30 mL/min/1.73 m² should not initiate empagliflozin for glycemic control (though it can be continued for cardioprotection per the label) [1].

If NAC is being taken at doses above 1,200 mg/day, hydration status should be re-evaluated, particularly during hot weather or illness.

Signs That Warrant Stopping or Adjusting

Contact your prescriber if you experience significant thirst, reduced urine output, dizziness on standing, or unexplained nausea while on empagliflozin and NAC together. These could reflect dehydration from empagliflozin's diuretic effect, not an NAC interaction, but the combination context matters.

What Guideline Bodies Say About SGLT2 Inhibitors and Supplements

The American Diabetes Association's 2024 Standards of Care in Diabetes state: "Patients should be asked about use of dietary supplements and herbal products, as these may affect glycemic control and interact with antidiabetic medications" [12]. The ADA does not list NAC specifically as contraindicated with any class of diabetes medication [12].

The Endocrine Society's 2021 Clinical Practice Guideline on type 2 diabetes management similarly recommends routine inquiry about supplement use but cites no specific prohibition for antioxidant supplements with SGLT2 inhibitors [13].

Practical Guidance for Patients Already Taking Both

If you are already taking NAC alongside empagliflozin, there is no reason to stop immediately based on current evidence. The combination does not appear to cause a pharmacokinetic conflict [1][5]. A few practical steps are worth following:

• Inform your prescriber that you are taking both.
• Take NAC and empagliflozin at any time of day; no dose-separation window is required by pharmacokinetic data.
• Keep total NAC dose at or below 1,200 mg/day unless a physician is supervising a higher dose for a specific indication.
• Stay well hydrated, aiming for at least 2 liters of water daily to offset empagliflozin's osmotic diuretic effect.
• Schedule a renal function check if you have not had one in the past 6 months.

Special Populations Requiring Extra Care

Older Adults

Adults over 65 have higher rates of baseline CKD and volume sensitivity. Empagliflozin's osmotic diuresis can cause falls due to orthostatic hypotension in this group. Adding NAC at high doses does not increase that risk directly, but any nausea from NAC could reduce oral fluid intake and worsen dehydration.

Patients with CKD Stage 3b or Higher

The EMPA-KIDNEY trial enrolled patients with eGFR as low as 20 mL/min/1.73 m² [9]. These patients showed benefit from empagliflozin but also showed larger absolute eGFR dips in the first few weeks. NAC's nephroprotective properties may theoretically be additive in this setting [10], but no dedicated trial has tested this. Physician supervision is required.

Patients Using Both for Liver Support

NAC is sometimes used off-label as a hepatoprotective agent. Empagliflozin has shown signals of benefit in non-alcoholic fatty liver disease (NAFLD) in small trials, including a 2022 study (N=84) that showed statistically significant reductions in liver stiffness (P<0.05) at 24 weeks with empagliflozin 10 mg [11]. Combining both for liver health is biologically plausible but currently unsupported by controlled trial data.

Key Takeaways for Prescribers

No pharmacokinetic interaction between NAC and empagliflozin has been documented in the primary literature or FDA labeling [1][5]. The combination is not contraindicated. The chief clinical consideration is shared renal physiology: both agents influence the proximal tubule environment, and patients with CKD, volume depletion, or concurrent diuretic use require closer follow-up. Baseline and periodic eGFR monitoring, as already required by the empagliflozin label, covers the main safety need [1].

Patients asking about this combination should receive a clear, honest answer: the evidence does not support avoiding NAC with Jardiance, but that answer comes with the expectation of routine renal monitoring and honest disclosure of all supplements to the prescribing team.